Sanofi

Diabetic patients challenge insulin makersIn the latest flap over the high cost of drugs, diabetes patients filed a class-action lawsuit against insulin makers.
Fasting regimens may be key in treating type 2 diabetesFasting regimens have gained popularity as a technique for reducing weight and obesity. This strategy may improve insulin sensitivity in patients with insulin resistance and diabetes.
Insulin makers accused of price collusionU.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices.
Importance of adherence and follow-up in patients with diabetic retinopathyA 37-year-old male came to my office for the first time in 2014 for a diabetes eye examination at the insistence of his primary-care provider (PCP).
Are PCSK9 inhibitors too pricey?
Are PCSK9 inhibitors too pricey?PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
New insulin drug to enter crowded marketNovo Nordisk is expected to find out in October whether FDA will approve its long-acting insulin Tresiba for sale in the US market. However, if approved, Tresiba faces growing competition from Sanofi, which markets the leading basal insulin Lantus along with Toujeo.
Newly approved PCSK9 inhibitor comes with hefty priceWhile the FDA’s approval of alirocumab (Praluent injection) for high cholesterol is an important new treatment for patients with cardiovascular disease, health plan executives and others are worried about the drug’s price tag.
FDA panel recommends approving Repatha, Praluent to lower cholesterolFDA’ s Endocrinologic and Metabolic Drugs Advisory Committee recommended this week to approve cholesterol-lowering drug evolocumab (Repatha) from Amgen in a 15-0 vote. It also voted 13-3 in favor of FDA approving Sanofi and Regeneron's Praluent (alirocumab), but most panel members called for a restricted label in high-risk patients with genetic conditions causing elevated cholesterol, rather than wider use in the general elevated cholesterol population.
IL-6 inhibitor shows positive clinical benefit in RA patientsSarilumab may be an effective option for patients with moderately-to-severely active rheumatoid arthritis (RA) according to topline results from a new study.